USFDA Guidance on Forms FDA 3542a and FDA 3542: Questions and Answers

Patent information plays a critical role in the regulatory framework for prescription drug approvals in the United States. Accurate submission of patent information helps ensure transparency regarding intellectual property protections associated with approved drug products and supports the operation of the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

To assist New Drug Application (NDA) applicants and NDA holders in meeting their patent submission obligations, the FDA has issued the guidance Forms FDA 3542a and FDA 3542: Questions and Answers. The guidance provides clarification on the appropriate use of Forms FDA 3542a and FDA 3542, explains patent listing requirements, outlines submission timelines, and addresses common questions related to patent information submitted to the Agency. The document is intended to help applicants submit complete and accurate patent information while ensuring compliance with applicable regulatory requirements.

Background of Patent Information Submission Requirements

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), NDA applicants and NDA holders are required to submit certain patent information related to approved drug products. These requirements support FDA's responsibility to publish patent information in the Orange Book and provide transparency regarding patents that may be associated with approved drugs.

Patent submissions generally relate to patents that claim:

• Drug substances (active ingredients)

• Drug products (formulations or compositions)

• Approved methods of use

The information submitted helps FDA maintain accurate Orange Book listings and supports the regulatory processes associated with generic drug development and approval.

Understanding Forms FDA 3542a and FDA 3542

The guidance explains that different forms must be used depending on the approval status of the NDA.

Form FDA 3542a

Form FDA 3542a is used when patent information is submitted for an unapproved NDA, amendment, or supplement.

This form applies when an NDA applicant wishes to submit information regarding patents that claim:

• A drug substance

• A drug product

• A method of using the drug

The form is submitted while the application is still under FDA review and before approval has been granted.

Form FDA 3542

Form FDA 3542 is used after approval of an NDA or NDA supplement.

NDA holders use this form to submit patent information for listing in the Orange Book once approval has been obtained. Information submitted through this form may subsequently be published by FDA as part of its Orange Book patent listings.

Understanding which form should be used is essential for ensuring that patent information is submitted through the correct regulatory pathway.

Patent Information Required by FDA

The guidance provides detailed information regarding the types of patents that should be submitted for listing.

Patent information generally includes:

• Patent number

• Patent expiration date

• Drug substance patent information

• Drug product patent information

• Method-of-use patent information

For drug substance patents, applicants should submit information only for patents that claim the active ingredient associated with the NDA. For drug product patents, submissions should relate to patents claiming the drug product described in the application. Method-of-use patents should relate only to approved or proposed conditions of use covered by the NDA.

Important Submission Timelines

The guidance emphasizes that patent information must be submitted within specific regulatory timelines.

For Approved NDAs

NDA holders are generally required to submit patent information:

• Within 30 days after NDA approval

• Within 30 days after approval of an NDA supplement

• Within 30 days after issuance of a new patent related to the approved product

Failure to meet these timelines may affect the timeliness of Orange Book patent listings and regulatory compliance.

Who Can Complete and Submit the Forms?

The guidance clarifies responsibilities associated with form preparation and submission.

Forms may be completed and signed by:

• NDA applicants

• NDA holders

• Patent owners

• Attorneys

• Agents

• Authorized representatives

However, only the NDA applicant or NDA holder may submit the completed forms directly to FDA under the NDA. Patent owners who are not NDA holders may assist with form preparation but cannot independently submit the forms to the Agency.

Submitting Patent Information to FDA

Patent information must be submitted through FDA's established electronic submission process.

The guidance emphasizes that NDA applicants and NDA holders should submit Forms FDA 3542a and FDA 3542 through the CDER Central Document Room using the Electronic Submissions Gateway.

Sponsors should avoid:

• Sending courtesy copies

• Submitting forms through alternative channels

• Sending duplicate submissions to Orange Book staff

• Using unauthorized submission methods

Following the correct submission pathway helps ensure timely processing and accurate regulatory recordkeeping.

By understanding the distinctions between Forms FDA 3542a and FDA 3542, adhering to submission requirements, maintaining accurate patent information, and following FDA's electronic submission procedures, NDA applicants and NDA holders can support regulatory compliance and ensure that patent information is submitted accurately and efficiently throughout the product lifecycle.

References

1. Forms FDA 3542a and FDA 3542: Questions and Answers